Case number 1:23-cv-00374
AbbVie, Inc. v. Teva Pharmaceuticals, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Oct 5, 2023 | 14 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,542,239 B2. (Attachments: # 1 Order)(nms) (Entered: 10/05/2023) (0) |
| Aug 16, 2023 | 13 | SO ORDERED Granting (D.I. 12 in 23-cv-374-RGA; D.I. 13 in 23-cv-607-RGA; D.I. 6 in 23-cv-750-RGA; D.I. 12 in 23-cv-448-RGA; D.I. 9 in 23-cv-684-RGA; D.I. 113 in 22-cv-1423-RGA-JLH; D.I. 13 in 23-cv-00470-RGA) Stipulation and Proposed Order Concerning Amended Complaint and Consolidation (see Order for further details). Signed by Judge Richard G. Andrews on 8/16/2023. Associated Cases: 1:22-cv-01423-RGA-JLH et al.(nms) (Entered: 08/16/2023) (7) |
| Aug 10, 2023 | 12 | STIPULATION and Proposed Order Concerning Amended Complaint and Consolidation, AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibits A-G, # 3 Supplemental ANDA form, # 4 Supplemental ANDA form, # 5 Supplemental ANDA form, # 6 Amended Patent Report, # 7 Exhibit 2)(Tigan, Jeremy) Modified on 8/10/2023 (nms). (Entered: 08/10/2023) (0) |
| Jul 24, 2023 | 11 | ANSWER to 9 Answer to Complaint and Counterclaims, by AbbVie Inc..(Tigan, Jeremy) Modified on 7/24/2023 (nms). (Entered: 07/24/2023) (6) |
| Jul 3, 2023 | 9 | ANSWER to 1 Complaint, Affirmative Defenses, COUNTERCLAIM against AbbVie Inc. by Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 07/03/2023) (15) |
| Jul 3, 2023 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals, Inc. filed by Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 07/03/2023) (1) |
| May 19, 2023 | 8 | SO ORDERED Granting 7 Stipulation and Proposed Order (*Reset Answer Deadlines: Teva Pharmaceuticals, Inc. answer due 7/3/2023). Signed by Judge Richard G. Andrews on 5/19/2023. (nms) (Entered: 05/19/2023) (5) |
| May 18, 2023 | 7 | STIPULATION and [Proposed] Order Regarding Teva Defendants by AbbVie Inc.. (Tigan, Jeremy) (Entered: 05/18/2023) (5) |
| May 4, 2023 | 6 | MOTION for Pro Hac Vice Appearance of Attorney Jennifer H. Roscetti, Danielle A. Duszczyszyn, William B. Raich, Constance P. Lee, Ryan V. McDonnell and Reinaldo Franqui Machin - filed by AbbVie Inc.. (Tigan, Jeremy) (Entered: 05/04/2023) (9) |
| May 4, 2023 | N/A | SO ORDERED, re (D.I. 6 in 23-cv-470-RGA; D.I. 6 in 23-cv-374-RGA; D.I. 6 in 23-cv-448-RGA) MOTION for Pro Hac Vice Appearance of Attorney Jennifer H. Roscetti, Danielle A. Duszczyszyn, William B. Raich, Constance P. Lee, Ryan V. McDonnell and Reinaldo Franqui Machin, filed by AbbVie Inc.. Signed by Judge Richard G. Andrews on 5/4/2023. Associated Cases: 1:23-cv-00374-RGA, 1:23-cv-00448-RGA, 1:23-cv-00470-RGA(nms) (Entered: 05/04/2023) (0) |
| Apr 5, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:23-cv-00362-RGA, 1:23-cv-00374-RGA (rjb) (Entered: 04/05/2023) (0) |
| Apr 3, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Teva Pharmaceuticals Industries Ltd., Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4104067.) - filed by AbbVie Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet) (vfm) (Entered: 04/03/2023) (Main Document) (16) |
| Apr 3, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 04/03/2023) (3) |
| Apr 3, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 02/21/2023. Date of Expiration of Patent: 07/29/2039.Thirty Month Stay Deadline: 1/23/2026. (vfm) (Entered: 04/03/2023) (1) |
| Apr 3, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,542,239 B2. (vfm) (Entered: 04/03/2023) (1) |
| Apr 3, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc.. (vfm) (Entered: 04/03/2023) (1) |
| Apr 3, 2023 | N/A | No Summons Issued. (vfm) (Entered: 04/03/2023) (0) |
| Apr 3, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Teva Pharmaceuticals Industries Ltd., Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4104067.) - filed by AbbVie Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet) (vfm) (Entered: 04/03/2023) (Exhibit A) (30) |
| Apr 3, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Teva Pharmaceuticals Industries Ltd., Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4104067.) - filed by AbbVie Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet) (vfm) (Entered: 04/03/2023) (Civil Cover Sheet) (2) |
